We found that CTNNBIP1 rs935072A>T was more effective to predict the platinum response in subgroups of patients who were older than 54 (adjusted OR=0.83, 95% CI=0.73-0.95, P=0.006), with a high grade (adjusted OR=0.90, 95% CI=0.83-0.99, P=0.022) or serous tumors (adjusted OR=0.83, 95% CI=0.72-0.97, P=0.020), with an advanced tumor stage (adjusted OR=0.88, 95% CI=0.80-0.98, P=0.017), and without neoadjuvant chemotherapy (adjusted OR=0.87, 95% CI=0.80-0.96, P=0.005). Here, CTNNBIP1 is linked to neoplasm.